4.7 Article

Evaluation of Gynecologic Cancer with MR Imaging, 18F-FDG PET/CT, and PET/MR Imaging

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 56, Issue 3, Pages 436-443

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.114.145011

Keywords

Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone) PET; 16 alpha-F-18-fluoro-17 beta-estradiol PET; diffusion weighted imaging; dynamic contrast enhanced MRI; perfusion MRI

Ask authors/readers for more resources

MR imaging and F-18-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available